WARNING: Bumetanide Injection is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dosage schedule have to be adjusted to the individual patient’s needs. (See
DOSAGE AND ADMINISTRATION.
Bumetanide is a loop diuretic, available in 4 mL and 10 mL vials for intravenous or intramuscular injection as a sterile solution.
Bumetanide injection is indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome.
Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route.
Successful treatment with bumetanide following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity.
Published Studies Related to Bumetanide
The use of bumetanide for oliguric acute renal failure in preterm infants. [2011.03]
OBJECTIVE: To determine the effects of bumetanide in preterm infants with oliguric acute renal failure (OARF)... CONCLUSIONS: Bumetanide therapy significantly increased urine output within 24-48 hrs, but its use was associated with a transient increase in serum creatinine level. Bumetanide can be used in preterm infants to reverse oliguria when therapy with furosemide fails. Prospective, randomized, controlled trials with long-term follow-up in preterm infants are necessary to establish the usefulness of bumetanide for OARF.
The use of bumetanide for oliguric acute renal failure in preterm infants. [2010.07.09]
OBJECTIVE:: To determine the effects of bumetanide in preterm infants with oliguric acute renal failure (OARF)... CONCLUSIONS:: Bumetanide therapy significantly increased urine output within 24-48 hrs, but its use was associated with a transient increase in serum creatinine level. Bumetanide can be used in preterm infants to reverse oliguria when therapy with furosemide fails. Prospective, randomized, controlled trials with long-term follow-up in preterm infants are necessary to establish the usefulness of bumetanide for OARF.
Loop Diuretics Increase Bone Turnover and Decrease BMD in Osteopenic Postmenopausal Women: Results From a Randomized Controlled Study With Bumetanide. [2006.01]
To study effects of loop diuretics on bone, 87 women were randomized to 1 year of treatment with bumetanide or placebo. Compared with placebo, bumetanide decreased BMD by 2% at the total hip and by 1.4% at the whole body. Levels of biochemical bone markers were lower in the placebo than in the bumetanide group. Thus, treatment with loop diuretics affects bone metabolism. INTRODUCTION: Loop diuretics may affect bone because they increase the renal calcium excretion and alters the diurnal rhythm of plasma PTH levels. We studied the effects of 1 year of treatment with the loop diuretic bumetanide on bone metabolism... CONCLUSIONS: Treatment with loop diuretics affects bone turnover and decreases BMD. Further studies may reveal whether loop diuretics should be considered as a risk factor for fracture.
Clinical Trials Related to Bumetanide
Bumetanide Versus Furosemide in Heart Failure [Withdrawn]
Patients with NYHA FC II-III heart failure will be randomized in a cross-over fashion to 8
weeks of bumetanide versus furosemide therapy (equipotent dose), to test whether bumetanide
therapy has a superior effect on insulin resistance compared to furosemide. Patients will be
subject to a frequently sampled intravenous glucose tolerance test (FSIGT) with minimal
model (MINMOD) analysis to assess insulin resistance and to a 6-minute walk test (6MWT) to
assess functional capacity; patient recruitment and retention success, as well as medication
adherence, will also be assessed.
Pilot Study of Bumetanide for Newborn Seizures [Recruiting]
The main goal of the study is to obtain pharmacokinetic and safety data of bumetanide in
newborns with refractory seizures. The overall hypothesis is that bumetanide, added to
conventional antiepileptic (antiseizure) medications, will be a safe and well tolerated
medication, compared with conventional antiepileptic drugs alone.
Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects [Completed]
To assess the potential pharmacokinetic (PK) interactions of bumetanide and dapagliflozin
following multiple doses of 1 mg bumetanide and 10 mg dapagliflozin in healthy subjects
Efficiency of Bumetanide in Autistic Children [Completed]
NEMO1:NEonatal Seizure Using Medication Off-patent [Completed]
NEMO is a multicentre pan European clinical trial with the aim to develop new treatment
strategies for the treatment of neonatal seizures using the loop diuretic bumetanide. There
is evidence that bumetanide improves GABAergic function of the current standard drug,
phenobarbitone. Bumetanide has been used as a diuretic in term and preterm babies for around
thirty years. This trial should confirm that Bumetanide in addition to standard treatment
will result in better seizures control.
Reports of Suspected Bumetanide Side Effects
Renal Failure Acute (35),
Blood Creatinine Increased (27),
Atrial Fibrillation (25),
Fluid Overload (24),
Toxic Epidermal Necrolysis (24),
Haemoglobin Decreased (23),
Stevens-Johnson Syndrome (21),
Oedema Peripheral (20),
DRY Skin (19),
Pruritus (18), more >>
Page last updated: 2011-12-09